(-0.02%) 5 477.25 points
(-0.05%) 38 799 points
(0.03%) 19 926 points
(0.25%) $80.53
(1.26%) $2.82
(0.14%) $2 332.30
(-0.29%) $29.31
(-0.24%) $968.60
(0.02%) $0.932
(-0.14%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada...
Stats | |
---|---|
Šios dienos apimtis | 3.91M |
Vidutinė apimtis | 2.05M |
Rinkos kapitalizacija | 794.69M |
EPS | $-0.0668 ( Q3 | 2023-11-06 ) |
Kita pelno data | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-17.43 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.410 (2.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-08 | Akkaraju Srinivas | Sell | 640 688 | Common Stock |
2023-11-08 | Akkaraju Srinivas | Sell | 8 111 | Common Stock |
2023-11-08 | Akkaraju Srinivas | Sell | 12 089 | Option to Purchase Common Stock |
2023-11-08 | Akkaraju Srinivas | Sell | 12 790 | Option to Purchase Common Stock |
2023-11-08 | Akkaraju Srinivas | Sell | 12 547 | Option to Purchase Common Stock |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 1 646 020 |
Tūris Koreliacija
Intercept Pharmaceuticals Koreliacija
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Intercept Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Intercept Pharmaceuticals Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $285.71M |
Bruto pelnas: | $284.73M (99.66 %) |
EPS: | $3.40 |
FY | 2022 |
Pajamos: | $285.71M |
Bruto pelnas: | $284.73M (99.66 %) |
EPS: | $3.40 |
FY | 2021 |
Pajamos: | $363.47M |
Bruto pelnas: | $360.37M (99.15 %) |
EPS: | $-2.88 |
FY | 2020 |
Pajamos: | $312.69M |
Bruto pelnas: | $307.37M (98.30 %) |
EPS: | $-8.34 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.